Market capitalization | $2.00b |
Enterprise Value | $2.00b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.34 |
P/S ratio (TTM) P/S ratio | 2.34 |
P/B ratio (TTM) P/B ratio | 8.40 |
Revenue growth (TTM) Revenue growth | 10.75% |
Revenue (TTM) Revenue | $854.35m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
23 Analysts have issued a Tandem Diabetes Care, Inc. forecast:
23 Analysts have issued a Tandem Diabetes Care, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 854 854 |
11%
11%
|
|
Gross Profit | 425 425 |
9%
9%
|
|
EBITDA | -117 -117 |
4%
4%
|
EBIT (Operating Income) EBIT | -134 -134 |
3%
3%
|
Net Profit | -127 -127 |
39%
39%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.
Head office | United States |
CEO | John Sheridan |
Employees | 2,400 |
Founded | 2006 |
Website | www.tandemdiabetes.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.